№ lp_1_2_22247
File format: docx
Character count: 36212
File size: 144 KB
Version:
HNY v3.0
Replaces version:
HNY v2.0
Clinical content last reviewed:
November 2023
Next review date:
July 2028
Local approval:
1st October 2025
Target population:
Adults aged 18 and over, excluding cancer care
Indications:
Licensed and off-label use in rheumatoid arthritis, Crohn’s disease, psoriasis, psoriatic arthritis, and other chronic inflammatory conditions
Administration routes:
Oral, subcutaneous
Monitoring requirements:
Blood tests, infection screening, vaccination advice, renal function assessment, pregnancy considerations
Responsible organizations:
HNY ICB, RDTC
Document type:
Shared Care Protocol
Contextual description:
Clinical guidance source detailing licensed and off-label methotrexate indications, administration, monitoring, and transfer protocols between specialist and primary care for adults in non-cancer services.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Region:
Gloucestershire, England, United Kingdom
Healthcare System:
National Health Service (NHS)
Type of Document:
Commissioning policy and prescribing guidance
Subject:
Prescribing policy for Tapentadol in non-cancer pain
Medication:
Tapentadol
Controlled Drug Classification:
Schedule 2 Controlled Drug
Clinical Area:
Pain management
Responsible Organisations:
Gloucestershire Clinical Commissioning Group; Gloucestershire Hospitals NHS Foundation Trust
Related Guideline:
Gloucestershire Joint Formulary
Prescribers Concerned:
Pain consultants, palliative care consultants, General Practitioners
Target Patient Group:
Adult NHS patients with severe non-cancer pain
Care Setting:
Primary and secondary care within Gloucestershire
Treatment Line Position:
Third-line opioid treatment
Funding Priority:
Low priority for NHS funding outside formulary recommendations
Monitoring Authority:
Clinical Commissioning Group (CCG)
Review Requirement:
Six-monthly clinical review and periodic reassessment of efficacy
Policy Scope:
Initiation, continuation, and review of Tapentadol prescribing in adults with severe non-cancer pain
Year:
2023
Region / city:
Australia
Theme:
Pharmaceutical submission
Document type:
Pharmaceutical submission
Organization / institution:
Pfizer Australia Pty Ltd
Author:
Not specified
Target audience:
Medical practitioners, nurse practitioners
Effective period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Context:
Pharmaceutical submission requesting the inclusion of a new formulation of methotrexate under the General Schedule of the PBS for Australia, with changes in packaging and excipient composition.
Note:
Year
Theme:
Rheumatology, Methotrexate Therapy, Drug Interaction
Document Type:
Medical Guidelines
Target Audience:
Healthcare Professionals, Specialists
Year:
2023
Region / city:
Australia
Topic:
Rheumatology, Pharmaceutical Listings
Document type:
Submission to Pharmaceutical Benefits Advisory Committee (PBAC)
Organization:
Link Medical Products Pty Ltd
Author:
Not specified
Target audience:
Healthcare professionals, PBAC members
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Context
Year:
2017-2018
Region / City:
Doncaster
Subject:
Healthcare
Document Type:
Service Specification
Organization:
NHS
Author:
Unknown
Target Audience:
Healthcare Providers (GPs, Specialists)
Period of Validity:
1st April 2017 to 31st March 2018
Approval Date:
Not specified
Date of Review:
Annual
Publication date:
March 2024
Version:
3.0
First published:
January 2015
Last updated:
December 2022
Region:
England
Type:
Clinical commissioning policy
Organization:
NHS England
Indication:
Toxic plasma methotrexate concentration due to delayed methotrexate elimination
Target population:
Adults and children receiving high-dose methotrexate chemotherapy
Therapeutic area:
Oncology / Haematology
Administration:
Urgent intravenous use
Expected annual use:
5–20 patients
Evidence base:
Phase II studies, case reports, pooled compassionate-use trials
Risk assessment:
Life-threatening methotrexate toxicity
Ethical framework:
NHS healthcare commissioning principles, Individual Funding Request guidance
Year:
2025
Region / City:
Humber and North Yorkshire
Subject:
Pharmaceutical guidelines, drug and treatment protocols
Document Type:
Decision summary
Organization:
HNY APC (Humber and North Yorkshire Area Prescribing Committee)
Author:
HNY APC
Target Audience:
NHS Healthcare Professionals
Approval Date:
2nd July 2025
Date of Changes:
June 2025
Year:
2023
Region / City:
Humber and North Yorkshire
Topic:
Learning and Development Policy
Document Type:
Policy
Organization:
Humber and North Yorkshire Integrated Care Board (ICB)
Author:
Senior Manager: Organisational Development & Learning and Development Lead
Target Audience:
ICB Employees
Approval Date:
07/09/2023
Amendment History:
7/9/23 - Updated policy from prior CCG organisations to ICB
Policy Number:
50
Version Number:
0.22
Equality Impact Assessment:
22/08/2023
Scope:
All Humber and North Yorkshire ICB employees
Mandatory Training:
Yes
Study Leave:
Yes
Year:
2025
Region / City:
Humber and North Yorkshire
Topic:
Establishment of Joint Committees
Document Type:
Report
Organization / Institution:
Humber and North Yorkshire Integrated Care Board
Author:
Natalie Caphane
Target Audience:
ICB Board members, Local Authority leaders
Period of Effect:
April 2025 - onwards
Approval Date:
March 12, 2025
Date of Changes:
N/A
Version:
HNY v1.0
Replaces version:
RDTC v1.0
Date published:
April 2025
Clinical content last reviewed:
October 2023
Next review date:
October 2025
Previous version publication date:
7th December 2023
Local approval date:
2nd April 2025
Approved by:
Humber and North Yorkshire ICB
Document type:
Shared Care Protocol
Therapeutic area:
Cardiology
Medicine:
Dronedarone
Target population:
Adults aged 18 years and over
Indication:
Maintenance of sinus rhythm after successful cardioversion in clinically stable adult patients with paroxysmal or persistent atrial fibrillation
Recommended dose:
400 mg twice daily with morning and evening meals
Initiation responsibility:
Specialist only
Prescribing restriction:
Not to be initiated in primary care for new patients
Monitoring requirements:
Liver function tests, urea and electrolytes including potassium and magnesium, serum creatinine, ECG
Regulatory references:
NICE TA 197; NICE NG 196
Intended audience:
NHS healthcare professionals
Geographical scope:
North West, North East and Yorkshire ICBs
Commercial use restriction:
Not permitted for commercial or marketing purposes
Year:
2025
Month:
November
Region:
Humber and North Yorkshire
Country:
United Kingdom
Document type:
Committee decision summary
Organisation:
Humber and North Yorkshire Area Prescribing Committee (HNY APC)
Approved by:
HNY APC
Date of approval:
3 December 2025
Reviewed by:
CPC
Scheduled review:
January meeting
Legal framework:
NICE technology appraisals implementation within NHS
Scope:
Medicines commissioning, formulary status, shared care protocols
Intended audience:
NHS healthcare professionals
Contact organisation:
HNY APC Professional Secretariat, Regional Drug and Therapeutics Centre, Newcastle upon Tyne
Usage restriction:
Not for commercial or marketing purposes